跳至主要内容
临床试验/NCT00792376
NCT00792376已完成4 期

"NSAIDs in Acute Achilles Tendinopathy: Effect on Pain Control, Leg Stiffness and Functional Recovery in Athletes"

Argentine Tennis Association1 个研究点 分布在 1 个国家目标入组 56 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
56
试验地点
1
主要终点
The pre-defined primary efficacy endpoint of the study is a 100-mm pain visual analog scale (P-VAS), where 0= no pain; 100= extreme pain.

研究概览

简要总结

The purpose of this study is to evaluate etoricoxib efficacy in pain control, leg stiffness and functional recovery of patients suffering acute Achilles tendinopathy.

It is hypothesized that etoricoxib (120mg orally/day/7 days) efficacy is not inferior to diclofenac (150mg orally /day/7 days) for pain control in subjects suffering acute Achilles tendinopathy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 50 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • Patients are eligible if they are male between 18 and 50 years of age and they suffer acute Achilles tendinopathy (<2 weeks). Diagnosis of Achilles tendinopathy is made by means of activity-related achillodynia, morning stiffness or pain, painful one-legged jumping test, tenderness and decreased sports performance (26). Subjects' age, race, affected tendon (right, left), activity, height and weight will be recorded.

排除标准

  • Patients are excluded from the study if they have:
  • Prior lower limb surgery or major trauma.
  • Bilateral Achilles tendinopathy.
  • History of lower limb radiculo-neuropathy or miopathy.
  • Hypersensitivity to any NSAIDs.
  • Used analgesic agents (NSAIDs, salicilates, narcotic) within 1 week
  • Concurrent medical/arthritic disease (e.g. gout, lupus, rheumatoid arthritis).
  • Other concurrent medical conditions including diabetes, hypertension, angina or congestive heart failure, ischaemic cardiopathy, malabsorption, morbid - Personal history of renal dysfunction, hepatic dysfunction or anemia
  • Used corticosteroids, clopidogrel bisulphate, rifampin, quinolon antibiotics, antiepileptics, muscle relaxants, warfarin, ticlopidine, glucosamine, condroitin sulphate for < 6 months prior to the study start. Patients taking low dose aspirin (100 mg) for cardioprotective benefit will be also excluded. Any other medication consumption will be considered by the investigator and the Ethical Committee.
  • Any other condition which, in the opinion of the investigator, could confound the study results or pose a risk to the patient (for example, co-morbid conditions for which NSAIDs are contraindicated).
  • History of psychotic illness, dementia or depression
  • History of drug or alcohol abuse or dependence.
  • Participated in any previous NSAIDs study and received active treatment, or in an investigational trial within 30 days prior to the first visit.
  • Inability to communicate or to cooperate with the investigator.

研究组 & 干预措施

etoricoxib

Experimental

etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days

干预措施: etoricoxib (Drug)

etoricoxib

Experimental

etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days

干预措施: diclofenac (Drug)

diclofenac

Active Comparator

diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.

干预措施: diclofenac (Drug)

结局指标

主要结局

The pre-defined primary efficacy endpoint of the study is a 100-mm pain visual analog scale (P-VAS), where 0= no pain; 100= extreme pain.

时间窗: 1 week

次要结局

  • The secondary study endpoints includes: the VISA-A Questionnaire, the Achilles Tendinopathy Scoring System (ATSS), PGART using a 5-point Likert scale and leg functional stiffness.(1 week)

研究者

发起方
Argentine Tennis Association
申办方类型
Other
责任方
Principal Investigator
主要研究者

Javier Maquirriain

MD

Argentine Tennis Association

研究点 (1)

Loading locations...

相似试验